

Supplementary table 1: peptides screened in the array

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|---------------|-------------------|---------------------------------------------|---------------------------------------------|
| IN 66-80 | THLEGKIIILVAVHVA | - | - |
| IN 66-80 T66A | AHLEGKIIILVAVHVA | - | - |
| IN 66-80 H67A | TALEGKIIILVAVHVA | - | - |
| IN 66-80 L68A | THAEGKIIILVAVHVA | - | - |
| IN 66-80 E69A | THLAGKIIILVAVHVA | - | - |
| IN 66-80 G70A | THLEAKIIILVAVHVA | - | - |
| IN 66-80 K71A | THLEGAIILVAVHVA | - | - |
| IN 66-80 I72A | THLEGKAILVAVHVA | - | - |
| IN 66-80 I73A | THLEGKIALVAVHVA | - | - |
| IN 66-80 L74A | THLEGKIIIAVAVHVA | - | - |
| IN 66-80 V75A | THLEGKIIILA AVHVA | - | - |
| IN 66-80 V77A | THLEGKIIILVAAHVA | - | - |
| IN 66-80 H78A | THLEGKIIILVAVAVA | - | - |
| IN 66-80 V79A | THLEGKIIILVAVHAA | - | - |
| IN 66-79 | THLEGKIIILVAVHV | - | - |
| IN 66-78 | THLEGKIIILVAVH | - | - |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|------------------|------------------------|---------------------------------------------|---------------------------------------------|
| IN 66-77 | THLEGKIIILVAV | - | - |
| IN 66-76 | THLEGKIIILVA | - | - |
| IN 66-75 | THLEGKIIILV | - | - |
| IN 66-74 | THLEGKIIIL | - | - |
| IN 66-73 | THLEGKII | - | - |
| IN 67-80 | HLEGKIIILVAVHVA | - | - |
| IN 68-80 | LEGKIIILVAVHVA | - | - |
| IN 69-80 | EGKIIILVAVHVA | - | - |
| IN 70-80 | GKIIILVAVHVA | - | - |
| IN 71-80 | KIILVAVHVA | - | - |
| IN 72-80 | IILVAVHVA | - | - |
| IN 73-80 | ILVAVHVA | - | - |
| IN 66-80 D-Thr66 | (D-T) HLEGKIIILVAVHVA | - | - |
| IN 66-80 D-His67 | T (D-H) LEGKIIILVAVHVA | - | - |
| IN 66-80 D-Leu68 | TH (D-L) EGKIIILVAVHVA | - | - |
| IN 66-80 D-Glu69 | THL (D-E) GKIIILVAVHVA | - | - |
| IN 66-80 D-Lys71 | THLEG (D-K) IILVAVHVA | - | - |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|------------------------|----------------------------|---------------------------------------------|---------------------------------------------|
| IN 66-80 D-Ile72 | THLEGK (D-I) ILVAVHVA | - | - |
| IN 66-80 D-Ile73 | THLEGKI (D-I) LVAVHVA | - | - |
| IN 66-80 D-Leu74 | THLEGKII (D-L) VAVHVA | - | - |
| IN 66-80 D-Val75 | THLEGKIIIL (D-V) AVHVA | - | - |
| IN 66-80 D-Ala76 | THLEGKIIILV (D-A) VHVA | - | - |
| IN 66-80 D-Val77 | THLEGKIIILVA (D-V) HVA | - | - |
| IN 66-80 D-His78 | THLEGKIIILVAV (D-H) VA | - | - |
| IN 66-80 D-Val79 | THLEGKIIILVA VH (DV) A | - | - |
| IN 66-80 D-Ala80 | THLEGKIIILVAVHV (D-A) | - | - |
| IN 66-80 (N-Me) -Thr66 | (N-Me) T-HLEGKIIILVAVHVA | - | - |
| IN 66-80 (N-Me) -Leu68 | TH- (N-Me) L-EGKIIILVAVHVA | - | - |
| IN 66-80 (N-Me) -Glu69 | THL- (N-Me) E-GKIIILVAVHVA | - | - |
| IN 66-80 (N-Me) -Gly70 | THLE- (N-Me) G-KIILVAVHVA | - | - |
| IN 66-80 (N-Me) -Lys71 | THLEG- (N-Me) K-IIILVAVHVA | - | - |
| IN 66-80 (N-Me) -Ile72 | THLEGK- (N-Me) I-ILVAVHVA | - | - |
| IN 66-80 (N-Me) -Ile73 | THLEGKI- (N-Me) I-LVAVHVA | - | - |
| IN 66-80 (N-Me) -Leu74 | THLEGKII- (N-Me) L-VAVHVA | - | - |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|-------------------------|-----------------------------|---------------------------------------------|---------------------------------------------|
| IN 66-80 (N-Me) -Val175 | THLEGKIIIL- (N-Me) V-AVHVA | - | - |
| IN 66-80 (N-Me) -Ala76 | THLEGKIIILV- (N-Me) A-VHVA | - | - |
| IN 66-80 (N-Me) -Val177 | THLEGKIIILVVA- (N-Me) V-HVA | - | - |
| IN 66-80 (N-Me) -Val179 | THLEGKIIILVA VH- (N-Me) V-A | - | - |
| IN 66-80 (N-Me) -Ala80 | THLEGKIIILVAVHV- (N-Me) A | - | - |
| | | | |
| IN 118-128 | GSNFTSTTVKA | 100 | 100 |
| IN 118-128 G118A | ASNFTSTTVKA | 77 | 116 |
| IN 118-128 S119A | GANFTSTTVKA | 146 | 177 |
| IN 118-128 N120A | GSAFTSTTVKA | 151 | 198 |
| IN 118-128 F121A | GSNATSTTVKA | 31 | 133 |
| IN 118-128 T122A | GSNFASTTVKA | 120 | 228 |
| IN 118-128 S123A | GSNFTATTVK | 182 | 135 |
| IN 118-128 T124A | GSNFTSATVKA | 107 | 231 |
| IN 118-128 T125A | GSNFTSTAVKA | 124 | 182 |
| IN 118-128 V126A | GSNFTSTTAKA | 64 | 129 |
| IN 118-128 K127A | GSNFTSTTVAA | 0 | 85 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|---------------------|-------------------|---------------------------------------------|---------------------------------------------|
| IN 118-127 | GSNFTSTTVK | 201 | 242 |
| IN 118-126 | GSNFTSTTV | 0 | 27 |
| IN 118-125 | GSNFTSTT | 0 | 19 |
| IN 118-124 | GSNFTST | 0 | 34 |
| IN 118-123 | GSNFTS | 0 | 0 |
| IN 119-128 | SNFTSTTVKA | 177 | 207 |
| IN 120-128 | NFTSTTVKA | 152 | 119 |
| IN 121-128 | FTSTTVKA | 280 | 236 |
| IN 122-128 | TSTTVKA | 111 | 135 |
| IN 123-128 | STTVKA | 187 | 144 |
| IN 118-128 D-Ser119 | G (D-S) NFTSTTVKA | 190 | 346 |
| IN 118-128 D-Asn120 | GS (D-N) FTSTTVKA | 144 | 133 |
| IN 118-128 D-Phe121 | GSN (D-F) TSTTVKA | 211 | 229 |
| IN 118-128 D-Thr122 | GSNF (D-T) STTVKA | 52 | 58 |
| IN 118-128 D-Ser123 | GSNFT (D-S) TTVKA | 124 | 92 |
| IN 118-128 D-Thr124 | GSNFTS (D-T) TVKA | 176 | 150 |
| IN 118-128 D-Thr125 | GSNFTST (D-T) VKA | 60 | 85 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|---------------------------|-----------------------|---------------------------------------------|---------------------------------------------|
| IN 118-128 D-Val126 | GSNFTSTT (D-V) KA | 107 | 97 |
| IN 118-128 D-Lys127 | GSNFTSTTV (D-K) A | 53 | 109 |
| IN 118-128 D-Ala128 | GSNFTSTTVK (D-A) | 137 | 136 |
| IN 118-128 (N-Me) -Gly118 | (N-Me) G-SNFTSTTVKA | 294 | 181 |
| IN 118-128 (N-Me) -Ser119 | G- (N-Me) S-NFTSTTVKA | 293 | 182 |
| IN 118-128 (N-Me) -Phe121 | GSN- (N-Me) F-TSTTVKA | 177 | 195 |
| IN 118-128 (N-Me) -Thr122 | GSNF- (N-Me) T-STTVKA | 200 | 165 |
| IN 118-128 (N-Me) -Ser123 | GSNFT- (N-Me) S-TTVKA | 279 | 312 |
| IN 118-128 (N-Me) -Thr124 | GSNFTS- (N-Me) T-TVKA | 197 | 249 |
| IN 118-128 (N-Me) -Thr125 | GSNFTST- (N-Me) T-VKA | 168 | 265 |
| IN 118-128 (N-Me) -Val126 | GSNFTSTT- (N-Me) V-KA | 215 | 273 |
| IN 118-128 (N-Me) -Lys127 | GSNFTSTTV- (N-Me) K-A | 191 | 185 |
| IN 118-128 (N-Me) -Ala128 | GSNFTSTTVK- (N-Me) A | 141 | 136 |
| | | | |
| IN 174-188 | TAVQMAVFIHNFKRK | 100 | 100 |
| IN 174-188 T174A | AAVQMAVFIHNFKRK | 80 | 83 |
| IN 174-188 V176A | TAAQMAVFIHNFKRK | 106 | 115 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|------------------|------------------|---------------------------------------------|---------------------------------------------|
| IN 174-188 Q177A | TAVAMAVFIHNFKRK | 79 | 83 |
| IN 174-188 M178A | TAVQAAVFIHNFKRK | 172 | 113 |
| IN 174-188 V180A | TAVQMAAFIHNFKRK | 222 | 123 |
| IN 174-188 F181A | TAVQMAVAIHNFKRK | 216 | 104 |
| IN 174-188 I182A | TAVQMAVFAHNFKRK | 254 | 156 |
| IN 174-188 H183A | TAVQMAVFIANFKRK | 121 | 122 |
| IN 174-188 N184A | TAVQMAVFIHAFKRK | 105 | 33 |
| IN 174-188 F185A | TAVQMAVFIHNNAKRK | 193 | 134 |
| IN 174-188 K186A | TAVQMAVFIHNFKARK | 176 | 91 |
| IN 174-188 R187A | TAVQMAVFIHNFKAK | 234 | 127 |
| IN 174-188 K188A | TAVQMAVFIHNFKRA | 209 | 109 |
| IN 174-187 | TAVQMAVFIHNFKR | 114 | 87 |
| IN 174-186 | TAVQMAVFIHNFK | 127 | 120 |
| IN 174-185 | TAVQMAVFIHNF | 0 | 0 |
| IN 174-184 | TAVQMAVFIHN | 0 | 0 |
| IN 174-183 | TAVQMAVFIH | 0 | 0 |
| IN 174-182 | TAVQMAVFI | 0 | 0 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|---------------------|-----------------------|---------------------------------------------|---------------------------------------------|
| IN 174-181 | TAVQMAVF | 0 | 0 |
| IN 175-188 | AVQMAVFIHNFKRK | 141 | 99 |
| IN 176-188 | VQMAVFIHNFKRK | 104 | 133 |
| IN 177-188 | QMAVFIHNFKRK | 135 | 122 |
| IN 178-188 | MAVFIHNFKRK | 88 | 106 |
| IN 179-188 | AVFIHNFKRK | 111 | 120 |
| IN 180-188 | VFIHNFKRK | 86 | 132 |
| IN 181-188 | FIHNFKRK | 69 | 133 |
| IN 174-188 D-Thr174 | (D-T) AVQMAVFIHNFKRK | 141 | 73 |
| IN 174-188 D-Ala175 | T (D-A) VQMAVFIHNFKRK | 209 | 105 |
| IN 174-188 D-Val176 | TA (D-V) QMAVFIHNFKRK | 226 | 115 |
| IN 174-188 D-Gln177 | TAV (D-Q) MAVFIHNFKRK | 173 | 154 |
| IN 174-188 D-Met178 | TAVQ (D-M) AVFIHNFKRK | 196 | 127 |
| IN 174-188 D-Ala179 | TAVQM (D-A) VFIHNFKRK | 194 | 142 |
| IN 174-188 D-Val180 | TAVQMA (D-V) FIHNFKRK | 152 | 108 |
| IN 174-188 D-Phe181 | TAVQMAV (D-F) IHNFKRK | 231 | 120 |
| IN 174-188 D-Ile182 | TAVQMAVF (D-I) HNFKRK | 108 | 99 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) * | IN binding – relative spot intensity- (%) * |
|---------------------------|---------------------------|---------------------------------------------|---------------------------------------------|
| IN 174-188 D-His183 | TAVQMAVFI (D-H) NFKRK | 105 | 105 |
| IN 174-188 D-Asn184 | TAVQMAVFIH (D-N) FKRK | 92 | 116 |
| IN 174-188 D-Phe185 | TAVQMAVFIHN (D-F) KRK | 156 | 112 |
| IN 174-188 D-Lys186 | TAVQMAVFIHNF (D-K) RK | 120 | 110 |
| IN 174-188 D-Arg187 | TAVQMAVFIHNFK (D-R) K | 169 | 93 |
| IN 174-188 D-Lys188 | TAVQMAVFIHNFKR (D-K) | 110 | 86 |
| IN 174-188 (N-Me) -Thr174 | (N-Me) T-AVQMAVFIHNFKRK | 93 | 84 |
| IN 174-188 (N-Me) -Ala175 | T- (N-Me) A-VQMAVFIHNFKRK | 86 | 75 |
| IN 174-188 (N-Me) -Val176 | TA- (N-Me) V-QMAVFIHNFKRK | 110 | 118 |
| IN 174-188 (N-Me) -Met178 | TAVQ- (N-Me) M-AVFIHNFKRK | 134 | 103 |
| IN 174-188 (N-Me) -Ala179 | TAVQM- (N-Me) A-VFIHNFKRK | 66 | 99 |
| IN 174-188 (N-Me) -Val180 | TAVQMA- (N-Me) V-FIHNFKRK | 55 | 67 |
| IN 174-188 (N-Me) -Phe181 | TAVQMAV- (N-Me) F-IHNFKRK | 152 | 141 |
| IN 174-188 (N-Me) -Ile182 | TAVQMAVF- (N-Me) I-HNFKRK | 107 | 123 |
| IN 174-188 (N-Me) -Phe185 | TAVQMAVFIHN- (N-Me) F-KRK | 50 | 122 |
| IN 174-188 (N-Me) -Lys186 | TAVQMAVFIHNF- (N-Me) K-RK | 70 | 130 |
| IN 174-188 (N-Me) -Arg187 | TAVQMAVFIHNFK- (N-Me) R-K | 75 | 123 |

| Peptide | Sequence | Rev binding – relative spot intensity (%) [*] | IN binding – relative spot intensity- (%) [*] |
|---------------------------|--------------------------|--------------------------------------------------------|--------------------------------------------------------|
| IN 174-188 (N-Me) -Lys188 | TAVQMAVFIHNFKR- (N-Me) K | 201 | 117 |

^{*} The intensity of the spots was estimated using ImageJ. For each spot, the intensity was averaged over the spot, and the background signal was subtracted from this signal. For each peptide, the relative signal compared to the non modified peptide is presented. No estimates were made for IN 66-80 due to the low intensity of the signals, and any spot for which the intensity was below the background was assigned an intensity of 0.